Kura Oncology (NASDAQ:KURA) Stock Price Up 4.1% – Here’s Why

Kura Oncology, Inc. (NASDAQ:KURA)’s share price traded up 4.1% during trading on Thursday . The company traded as high as $7.47 and last traded at $7.57. 30,728 shares traded hands during trading, a decline of 97% from the average session volume of 1,051,821 shares. The stock had previously closed at $7.27.

Wall Street Analyst Weigh In

KURA has been the subject of a number of recent analyst reports. Scotiabank lowered their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. StockNews.com lowered Kura Oncology from a “buy” rating to a “hold” rating in a report on Tuesday. JMP Securities restated a “market outperform” rating and issued a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.50.

Kura Oncology Price Performance

The business’s 50 day moving average is $7.81 and its 200-day moving average is $12.61. The firm has a market capitalization of $618.26 million, a P/E ratio of -3.24 and a beta of 0.85. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. As a group, sell-side analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,729 shares of company stock worth $92,307. 5.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in KURA. Virtus ETF Advisers LLC increased its holdings in Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after purchasing an additional 3,061 shares in the last quarter. Harbor Advisors LLC bought a new stake in shares of Kura Oncology in the 4th quarter valued at $87,000. E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology in the 4th quarter valued at $90,000. Corton Capital Inc. bought a new stake in Kura Oncology in the 4th quarter valued at about $99,000. Finally, Optimize Financial Inc acquired a new position in Kura Oncology during the 4th quarter worth approximately $100,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.